Roche: 9m sales up 7%

(CercleFinance.com) - Roche has unveiled 9m 2018 sales that are up 7% (+6% at constant exchange rates) at 42.
1 billion Swiss francs, with similar growth at its pharma and diagnostics divisions.

The Swiss health group states that its main growth drivers include the recently marketed drugs Ocrevus, which is used for the treatment of two forms of multiple sclerosis, and the anticancer drugs Pertoss, Alecensa and Tecentriq.

For FY 2018, Roche confirms its forecasts for mid-single-digit sales growth, with mid double-digit growth in adjusted EPS, at constant exchange rates.



Copyright (c) 2018 CercleFinance.com. All rights reserved.